Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sight Sciences, Inc.NASDAQ: SGHT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.55M fell 42.5% year over year, behind the -28.5% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -13.9% a year.
Context
- Research & development amounted to 18.9% of revenue in FY2025, down 3.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -42.5% toward the trailing-twelve-month pace of -28.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.61M USD
- Year-over-year change
- -18.8%
- 4-year CAGR
- -1.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.61M | -18.8% |
| FY2024 | 2024-12-31 | 17.99M | +2.5% |
| FY2023 | 2023-12-31 | 17.56M | -23.2% |
| FY2022 | 2022-12-31 | 22.86M | +46.2% |
| FY2021 | 2021-12-31 | 15.63M | — |
Research & Development vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's LTM Mar 2026 research & development of $12.72M is the lowest of the 7 companies compared; the peer median is $198.81M.
- Its year-over-year change of -28.5% is the lowest of 6, against a peer median of +26.4%.
- Research & development amounts to 16.0% of revenue for SGHT, versus a peer median of 13.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.44B | +51.4% | +12.1% | 13.1% | |
| LTM Jun 2026 | $634M | +1.3% | +5.9% | 5.8% | |
| LTM Mar 2026 | $220.45M | +47.2% | +54.5% | 423.6% | |
| LTM Jun 2026 | $177.17M | +26.4% | +6.9% | 28.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $28.64M | — | — | — |
| LTM Mar 2026 | $15.36M | +17.2% | +61.5% | 5.7% | |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| Peer median (excluding SGHT) | $198.81M | +26.4% | +12.1% | 13.1% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M |
| Cost of Revenue | 8.61M | 12.36M | 11.88M | 11.58M | 10.7M |
| Gross Profit | 40.35M | 58.97M | 69.18M | 68.29M | 66.67M |
| Gross Margin | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Research & Development | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M |
| Selling, General & Admin | 76.19M | 120.07M | 108.89M | 100.83M | 89.16M |
| Operating Expenses | 91.82M | 142.92M | 126.45M | 118.82M | 103.77M |
| Depreciation & Amortization | 1.2M | 1.25M | 614K | 712K | 487K |
| EBITDA | (57.21M) | (80.48M) | (49.42M) | (45.9M) | (32.79M) |
| EBITDA Margin | -116.8% | -112.8% | -61.0% | -57.5% | -42.4% |
| Operating Income | (51.48M) | (83.95M) | (57.27M) | (50.53M) | (37.1M) |
| Operating Margin | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.97M |
| Interest Expense | 4.37M | 4.47M | 5.41M | 4.66M | 5.14M |
| Other Income / Expenses | (11.29M) | (2.24M) | 1.84M | (739K) | (1.32M) |
| Income Before Tax | (62.77M) | (86.2M) | (55.44M) | (51.27M) | (38.42M) |
| Pre-Tax Margin | -128.2% | -120.8% | -68.4% | -64.2% | -49.7% |
| Income Tax Expense | 188K | 47K | 110K | 236K | 10K |
| Net Income | (62.96M) | (86.24M) | (55.55M) | (51.51M) | (38.43M) |
| Net Margin | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| EPS (Basic) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| EPS (Diluted) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| Weighted Avg Shares | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
| Weighted Avg Shares (Diluted) | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.